American Association for Cancer Research, 2025
Demonstration of an Isoform-Specific Anti-inflammatory Role for Neuropilin-2 Through a Novel Interaction with the Chemokine Ligand 21
Keystone Symposia: Myeloid Cell Diversity, 2024
Inhibition of VEGF Binding to Neuropilin-2 Enhances Chemosensitivity and Inhibits Metastasis in Triple-Negative Breast Cancer
Xu Z, Goel HL, Burkart C, Burman L, Chong YE, Barber AG, Geng Y, Zhai L, Wang M, Kumar A, Menefee A, Polizzi C, Eide L, Rauch K, Rahman J, Hamel K, Fogassy K, Klopp-Savino S, Paz S, Zhang M, Cubitt A, Nangle LA, Mercurio AM.
Science Translational Medicine (2023)
Therapeutic Blocking of VEGF Binding to Neuropilin-2 Diminishes PD-L1 Expression to Activate Antitumor Immunity in Prostate Cancer
Wang M, Wisniewski CA, Xiong C, Chhoy P, Goel HL, Kumar A, Zhu LJ, Li R, St. Louis PA, Ferreira LM, Pakula H, Xu Z, Loda M, Jiang Z, Brehm MA, Mercurio AM.
Science Translational Medicine (2023)
Resistance to Cancer Therapy via Upregulation of the NRP2/VEGF-C Axis Can Be Neutralized By ATYR2810
American Association for Cancer Research, 2023
ATYR2810, a Fully Humanized Monoclonal Antibody Targeting the VEGF-NRP2 Pathway Sensitizes Highly Aggressive and Chemoresistant TNBC Subtypes to Chemotherapy
American Association for Cancer Research, 2022
ATYR2810 an Anti-NRP2 Monoclonal Antibody Targets Tumor Associated Macrophages
Society for Immunotherapy of Cancer, 2021
Engineering an Anti-Neuropilin-2 (NRP2) Antibody that Selectively Blocks NRP2 Interactions with Semaphorin and Plexin
Antibody Engineering & Therapeutics Europe, 2021
ATYR2810, a Neuropilin-2 antibody, selectively blocks the NRP2/VEGFR signaling axis and sensitizes aggressive cancers to chemotherapy
Keystone Symposia: Cancer Stem Cells, 2021
The Neuropilin-2 Targeting Antibody ATYR2810 Inhibits Non-Small Cell Lung Cancer Tumor Growth in Monotherapy and Combination Therapy
American Association for Cancer Research, 2021